Regulatory Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy Pharmaceutical TechnologyPfizer and Astellas have received FDA acceptance for priority review of their sBLA for perioperative Padcev combined with Keytruda for MIBC.RegulatoryOncologyRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) Pharmaceutical Technology Pfizer and Astellas have received FDA acceptance for priority review of their sBLA for perioperative Padcev combined with Keytruda for MIBC. RegulatoryOncologyRead full story Post navigation Previous: Italy leads the way on child genetic disease diagnosisNext: Asahi Kasei acquires German company Aicuris Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026